- Home
- YSG vs SLGL Comparison
YSG vs SLGL Comparison
Compare YSG & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YSG | SLGL |
|---|---|---|
| Founded | 2016 | 1997 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.5M | 247.1M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | YSG | SLGL |
|---|---|---|
| Price | $2.16 | $63.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 104.3K | 13.5K |
| Earning Date | 05-15-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.08 | N/A |
| Revenue Next Year | $9.45 | $223.84 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.30 | $6.80 |
| 52 Week High | $11.04 | $97.97 |
Technical Indicators
Market Signals| Indicator | YSG | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 21.63 | 40.03 |
| Support Level | N/A | $61.92 |
| Resistance Level | $3.10 | $67.85 |
| Average True Range (ATR) | 0.18 | 5.06 |
| MACD | -0.05 | -0.73 |
| Stochastic Oscillator | 0.53 | 3.77 |
Price Performance
Historical ComparisonAbout YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.